Breaking AI & Tech News Analyzed

Executive Summary: Emerging Hope in Cancer TreatmentThe latest ASCO conference showcased several promising therapies, most notably daraxonrasib, which doubled median survival for pancreatic cancer patients from six to thirteen months. While a cure remains distant, these incremental gains illustrate how sustained research and genetic screening are reshaping oncology.ASCO Highlights: Daraxonrasib and Other BreakthroughsBeyond the pancreatic trial, the meeting featured a new jab for head‑and‑neck cancers and an immunotherapy that could spare bladder‑cancer patients from invasive surgery. Together, these advances underscore a shift from seeking a single "magic bullet" to building a portfolio of targeted options.Survival Gains: Daraxonrasib Doubles Pancreatic Cancer SurvivalMedian survival: 13 months vs. 6 months in the control arm.Target: Mutated Ras proteins, long considered “undruggable”.Potential reach: Trials are expanding to colorectal (≈40% Ras‑mutated) and small‑cell lung cancers (≈30%).These figures translate into precious additional time for patients and their families, echoing the incremental progress seen in HIV treatment decades ago.Broader Impact: Shifting the Landscape of OncologyThe success of daraxonrasib validates two emerging trends: (1) persistent, incremental research can eventually overcome seemingly impossible targets, and (2) routine genetic screening now enables clinicians to match patients with niche therapies quickly, expanding the utility of each new drug.In the UK, cancer survival rates have doubled since the 1970s, a trend mirrored across high‑income nations, reinforcing the view of a "golden age for cancer research" championed by Michelle Mitchell of Cancer Research UK.Looking Ahead: Ras‑Targeted Therapies and Personalized MedicineWith Ras now druggable, the next decade will likely see a cascade of trials testing similar inhibitors across multiple tumor types. Combined with expanding genomic profiling, this could accelerate the move toward truly personalized oncology, where each patient receives a regimen tailored to their tumor’s molecular fingerprint.

The New Era of Veteran FootballersAfter playing at Qatar 2022 at age 35, US national team defender Tim Ream thought it was "pretty unlikely" he could play in another World Cup. But he decided he would at least try to stay in the game as long as possible. "Because for me, it's about pushing boundaries, pushing myself, pushing the limits of what I can physically and emotionally handle," he told Al Jazeera.Last week, Ream was named as the US's captain for the upcoming football tournament in North America and, at 38, is the oldest ever outfield player in a US World Cup squad. "To be given the honour and the opportunity to wear the captain's armband in a home World Cup is incredible," he said.Ream is one of several outfield players in their late 30s and beyond at the 2026 World Cup; including Portugal superstar Cristiano Ronaldo, 41, the 40-year-olds Luka Modric and Edin Dzeko, Yuto Nagatomo, 39, and Argentina legend Lionel Messi, who turns 39 later this month.The Science Behind Extended CareersEvolving sport science plays a significant role in extending career longevity – the days when "recovery" meant having a few beers after the game are long gone, and many players now extoll all kinds of developments from lymphatic draining to cryotherapy.Huge amounts of data measuring biomarkers from heart rate variability and muscle oxygenation to hormonal fluctuations and inflammation are now available, including from wearable technology. But experts argue that sport science is just part of a complex system of interlocking factors needed to extend longevity in football, including culture, relationships, a learning mindset, luck, resources, and the motivation to keep going into a fifth decade."This question is always about people," Vlatko Vucetic, a professor of kinesiology at the University of Zagreb who has worked as a personal trainer with Croatian and Real Madrid star midfielder Modric for more than 10 years, told Al Jazeera.The Statistical Shift in Football LongevityFootballers tend to peak before the age of 30, with research suggesting a general decline in the early 30s in terms of speed, power and explosiveness, although endurance fades more slowly. As players age, recovery takes longer, and they also become more susceptible to injuries. Football has also gotten much faster and more physical over the last few decades, and the number of matches at the elite level has increased dramatically.According to Transfermarkt.com, only 15 players aged 35 or above appeared in the Premier League this season out of more than 500 players. However, there is evidence that the median age of footballers may be increasing, while the number of outfield players playing into their late 30s and early 40s at the upcoming World Cup is striking. Before this tournament, Cameroon's Roger Milla – who scored at USA 1994 aged 42 – was the only outfield player in their 40s to play at a World Cup.How Aging Stars Are Transforming Football CultureBen Rosenblatt was the lead performance coach for the England men's team for seven years and is the founder and director of 292 Performance, a sport consultancy firm that trains and advises elite individuals and organisations. He told Al Jazeera that advances in sport science and data collection – and an increased focus on health and wellness culture inside and outside the game – have helped extend careers in football."Within the game, there is more attention to detail over the last two decades being placed on an understanding and knowledge around training science and in particular, how to schedule organised training sessions to optimise athletes' performance and reduce injury risk – which is obviously going to be a big survival factor for players," he said.While Rosenblatt says longevity relies on "the amalgamation of all the different tools, resources, culture and behavioural shifts that are taking place within the game", the fundamentals remain crucial; training, recovery, sleep, lifestyle, nutrition and hydration."It's about doing the stuff that's quite boring and basic 99 percent of the time," he said.The Future of Athletic Longevity in FootballLooking ahead, Rosenblatt says putting the huge amount of available data together to create a more holistic picture of a player could be "transformative" for longevity. "That's kind of the Holy Grail, because you can give clarity to a manager or an owner game by game or across the course of a season about what the player is capable of delivering, and then obviously what development they require," he said.And extending longevity means establishing routines, discipline, and what works early on. "I know so many players who, towards the end of their career, tried to find a routine and they couldn't stick with it because they hadn't done it early enough," Ream said. "Find these things and get into them early, because it'll help you in the long run."Veterans playing into middle age will often adapt their game to compensate for slowing legs with assets like enhanced vision. "I think my biggest improvement is being able to see things as they're developing, and as they're happening, but then also understanding and adapting to different coaches," Ream said. "I think that's where you have to understand the interpersonal side with this game, because it's all about connections, it's all about communication, it's all about relationships on and off the field."

The Power of Football in RecoverySarah Rhind, a 42-year-old goalkeeper and Street Soccer charity coordinator, has a powerful message about how football saved her from heroin addiction. In her recently published autobiography, "Scars Under The Jersey," Rhind details her journey through addiction, recovery, and the transformative role football played in her life. "I can wholeheartedly say that without it I wouldn't be in the position that I'm in now – if I was even lucky enough to still be here," she states emphatically.From Participant to Coordinator: Football as LifelineWhat makes Rhind's story particularly striking is her journey from participant to coordinator at Street Soccer, a charity that provides free sessions for at-risk and socially disadvantaged people. Before working for the organization, Rhind was a participant who relied on the weekly sessions to stay clean. "There were times where I'd come through a really rough weekend, struggling with thoughts of using and relapsing but hadn't done it," she recalls. "There were many times where the reason was literally: 'If I use, I can't go to football on Tuesday.'"Mental Health and the Pitch: A Sanctuary from NoiseRhind describes football as a sanctuary from the "mental noise" that consumed her life. "My mind is 24/7 from the minute I wake up to the minute I go to sleep at night; it's 20 tabs open and they're all about different things," she explains. "When I'm on the pitch and playing football the focus is just on that, because that was most important. It's like a transition happens. I get my boots on and step on to the pitch and I find it is the only place that I am able to leave the mental noise."Breaking Barriers: Women's Football and InclusionNow representing Scotland at international events like the Homeless World Cup (2015) and playing in the Scottish top flight with Hamilton Academical, Rhind is passionate about creating opportunities for women in football. She notes that women of her age have "missed out so much" compared with younger generations benefiting from the growth of the women's game. "I hear all the time: 'I'm not fit enough, not strong enough, I can't play football,'" she says. "When did society become so about having to be really good at something that you can't just try it or to have fun with it?"The Healing Power of StorytellingWriting her autobiography was a cathartic experience for Rhind, who found the process to be "an incredible platform for healing." She particularly struggled with documenting moments of suicidal thoughts, noting that "it had taken me a couple of weeks to actually be able to write a sentence out about being suicidal." The act of writing, however, became therapeutic. "I just wrote it and I remember it so clearly: I just sat and looked at that sentence and realised what a powerful form of therapy that process had been," she reflects.A New Chapter: Continuing the JourneyFor Rhind, recovery is an ongoing process. "Life is hard and that's always going to be the case; things are going to keep happening," she acknowledges. "But, hopefully, I can keep building my toolbox of coping mechanisms for dealing with those things when they come, and keep talking." Through her work with Street Soccer and sharing her story, Rhind continues to help others find their path through darkness, using football as both a literal and metaphorical lifeline.

Podcast Overview: Red‑Light Masks and Ageing ClaimsThe Guardian’s latest science podcast asks the question, “Is it true that red‑light therapy masks prevent wrinkles?” It invites listeners to explore the evidence behind a popular anti‑ageing gadget.What the Episode CoversIntroduction to red‑light therapy and its purported skin‑benefits.Interviews with dermatologists and researchers discussing clinical findings.Consumer perspectives on the rise of at‑home light‑mask devices.Current Evidence LandscapeWhile some small studies suggest modest improvements in skin texture, the podcast notes the lack of large‑scale, peer‑reviewed trials confirming long‑term wrinkle reduction.Implications for Consumers and the Beauty IndustryThe discussion highlights a growing market for home‑use light devices, prompting regulators to consider clearer labelling and efficacy standards.Looking Ahead: Research and RegulationFuture episodes may track upcoming clinical trials and potential guidance from health authorities on the safe use of red‑light masks.

The Rise of Sound Baths in Wellness Culture In an era where digital detoxes and mindfulness practices have become mainstream, a new wellness trend has emerged: sound baths. These experiences, where participants pay to lie on mats while practitioners play singing bowls, chimes, and gongs, have seen online interest rise exponentially in the last decade. From Sydney Harbour settings to high-end wellness clubs with surround-sound chambers, the industry is capitalizing on claims that these sonic experiences can "soothe and calm your nervous system" with sounds that "penetrate every cell in your body." But as this trend grows, questions arise about whether these expensive experiences deliver on their promises. The Science Behind Sound and Relaxation "There's a rich field of music psychology that's all about the impacts of different types of sounds on human psychology and human physiology," explains Dr Vince Polito, a senior lecturer in psychological sciences at Macquarie University. Experts suggest that while specific frequencies may not have the mystical healing properties claimed by practitioners, the experience can still be beneficial. Dr Sandra Garrido, a senior research fellow at the University of Sydney's school of psychology, notes that "like anything in the wellness space, its benefits can definitely be talked up." The effects of sound or music on wellbeing largely relate to how we perceive and interpret those sounds, rather than specific types or frequencies. Research Evidence on Sound Meditation Studies on sound baths and similar practices offer some insight into their potential benefits. A 2016 observational study found that people who participated in a meditation session involving Tibetan singing bowls reported feeling less tension, anger and fatigue afterward. Another randomized controlled trial in breast cancer patients linked Tibetan sound meditation to improved cognitive function and mental health. However, researchers note that mindfulness meditation itself has been independently linked to improvements in anxiety, depression and insomnia, making it difficult to isolate the specific effects of sound. Sound Baths vs. Music Therapy While sound baths have gained popularity in wellness circles, they differ significantly from music therapy, a regulated profession with a long history of therapeutic use. "There are long histories of using music and sound in therapeutic ways," says Dr Amanda Krause, a senior lecturer in psychology and president of the Australian Music and Psychology Society. Music therapists work with a range of clients in schools and hospitals, using music listening or production to improve psychological and physical health. Unlike sound bath practitioners, music therapists are registered professionals with standardized training and ethical guidelines. The Social Connection Factor One potential benefit of sound baths that researchers acknowledge is the social aspect of the experience. "Historically, throughout most of human history... music has been about social connection," Garrido explains. "It's only in the last 100 years or so that we've had the capacity to go home and listen to music on our own in an isolating kind of way." The communal experience of a sound bath can create a sense of connection that's increasingly rare in our digital, often isolated lives. "Communally listening to music in the experience of a sound bath can be a 'helpful, healthy thing,'" Garrido adds. The Future of Sound Wellness As the wellness industry continues to evolve, sound baths may find their place alongside other mindfulness practices, though perhaps not as the "miracle cure" some marketing suggests. "I've been to them myself," Garrido admits. "I enjoy them, they can be relaxing, it's a nice experience – but I wouldn't pay too much money for it." The future of sound wellness likely involves a more balanced approach that acknowledges both the potential benefits of focused listening and the importance of not overclaiming what the science can support. As with many wellness trends, the key may be finding practices that work for individuals without requiring expensive or mystical explanations.

The Lead Doctors, scientists, and researchers shared new research about ways to tackle cancer at the 2026 American Society of Clinical Oncology (Asco) annual meeting, the world's largest cancer conference. Breakthroughs in Cancer Treatment The event in Chicago, attended by 40,000 health professionals, featured more than 200 sessions and 2,700 poster presentations on this year's theme, “the science and practice of translation: improving cancer outcomes worldwide”. Smart Drugs in Cancer Treatment Researchers have developed a smart drug that stops cancer cells hiding. The experimental tablet, GRWD5769, can help shrink tumours by at least 30% in six of the world’s most common forms of the disease, delegates in Chicago were told. 26 of 83 patients with cervical, bladder, liver, bowel, lung or head and neck cancers who were given GRWD5769 alongside cemiplimab had tumour reductions of at least 30%. 15 had tumour reductions of at least 30%. A Daily Pill for Pancreatic Cancer A pill that doubles survival time in patients with pancreatic cancer was presented at the conference. In a trial of 500 patients, all of whom had pancreatic cancer that had spread, the pill, daraxonrasib, doubled survival time, with fewer side-effects compared with chemotherapy. Patients who took the drug lived substantially longer, for an average of 13.2 months, compared with 6.6 to 6.7 months for patients who had chemotherapy. Safely Skipping Some Treatments Some patients can safely skip some treatments, according to research presented at the conference. A genomic test could pave the way for a new era of personalised medicine, enabling doctors to determine which patients can safely skip chemotherapy. The Optima trial, led by University College London, followed 4,000 patients with newly diagnosed breast cancer in the UK, Norway, Sweden, Australia, New Zealand and Thailand. Those with a low score on the genomic test could be treated safely with hormone therapy alone. The Future of Cancer Treatment Urgent action is required to cope with rising cancer cases. The world faces a cancer workforce crisis, experts said, with a shortage of 100 million staff expected by 2050 when 100,000 people will be being diagnosed every day. A 21% increase in cancer incidence is predicted, according to a report presented at the conference. The rate is set to rise from 165 per 100,000 people in 2025 to 200 per 100,000 in 2050.

GLP‑1 Medications Show Promise in Reducing Breast Cancer IncidenceRecent analyses presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago suggest that patients using GLP‑1 receptor agonists—a class of weight‑loss drugs—experienced a 30% lower likelihood of being diagnosed with breast cancer compared with non‑users.Study cohort: 110,000 women aged 45‑80.Risk reduction: 30% for breast cancer onset.Lead researcher: Dr Elizabeth McDonald, University of Pennsylvania.Adjunctive Use of GLP‑1 Drugs Cuts Breast Cancer MortalityA separate investigation involving 27,000 breast‑cancer patients in Italy reported that adding a GLP‑1 agent to standard therapy was associated with a 30% decrease in cancer‑related death.Institution: IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola.Outcome: 30% lower mortality risk.Broad Cancer‑Spread Benefits Observed Across Multiple Tumor TypesData from the Cleveland Clinic, covering 12,000 patients with breast, lung, colorectal or liver cancer, indicated a 38‑50% reduction in progression to stage‑four disease among GLP‑1 users.Study size: 12,000 patients.Risk reduction range: 38%–50% for metastatic spread.Why These Findings Matter for Public Health and OncologyThe consistency of risk‑reduction signals across incidence, mortality and metastasis points to a potential paradigm shift: drugs originally designed for diabetes and obesity may become adjunct tools in cancer prevention and treatment. If confirmed, the impact could be substantial given the prevalence of obesity and the high incidence of breast cancer worldwide.Next Steps: Clinical Trials and Regulatory ConsiderationsExperts caution that the current evidence is observational. Ongoing randomized controlled trials will be needed to disentangle the effects of weight loss from direct pharmacologic actions of GLP‑1 agonists. Regulatory bodies may eventually evaluate these agents for oncologic indications, pending robust trial data.

A New Lease on Life for Stage Four PatientsThe landscape of terminal cancer treatment is witnessing a potential turning point following the success of a pioneering smart drug. Pat Brogan, a 68-year-old from Cowdenbeath, Scotland, who was diagnosed with stage four lung cancer in 2021, has seen his tumors shrink by almost a third after joining a clinical trial in 2025. The breakthrough offers a stark contrast to his initial prognosis, allowing him to anticipate major life milestones previously thought impossible.The Mechanism Behind GRWD5769The core of this clinical breakthrough lies in the smart drug GRWD5769. Traditional immunotherapies sometimes fail because cancer cells develop an invisibility cloak, effectively hiding from the body's immune defenses. GRWD5769 disrupts this camouflage. By disabling the cloaking mechanism, the drug clears the path for standard immunotherapy to locate, target, and eradicate the disease cells. This combination approach was recently highlighted at the world’s largest oncology conference in Chicago.Measurable Tumor Reduction and Patient OutcomesThe clinical data translates directly into profound quality-of-life improvements for patients like Brogan. Prior to the trial, Brogan had undergone three years of chemotherapy and immunotherapy before his tumors began growing again. The introduction of GRWD5769 yielded rapid, tangible results:Almost 33% reduction in overall tumor size.Restored ability to live a relatively normal life despite a stage four diagnosis.Capacity to resume daily activities, including daily walks and international travel.Brogan, who previously prepared to say his goodbyes, is now planning a trip to Spain and preparing to walk his daughter down the aisle in June.Shifting the Paradigm in Immunotherapy ResistanceBrogan's case represents a critical victory in the ongoing battle against treatment-resistant cancers. When standard immunotherapy fails, patients are often left with highly toxic, intensive chemotherapy alternatives with low success rates. The success of GRWD5769 demonstrates that overcoming cellular resistance—rather than just bombarding the body with harsh chemicals—can yield better survival rates and vastly superior patient quality of life. The work led by Prof Stefan Symeonides and his team in Edinburgh underscores the value of targeted clinical research contributing to global oncological advancements.The Future of Targeted Oncology TrialsAs the medical community digests the findings presented in Chicago, the focus will inevitably shift toward expanding the trial parameters for GRWD5769. If larger cohorts mimic Brogan's success, this mechanism of stripping away a tumor's invisibility could become a standard adjunct to immunotherapy across various cancer types. For patients who have exhausted conventional options, these smart drugs represent the next vital frontier in extending both life expectancy and quality of life.

Breakthrough Cancer Drug Reveals Hidden TumorsA smart drug that stops cancer cells "hiding" from treatment can shrink tumours by at least 30% in six of the world's most common forms of the disease, according to early trial results. While immunotherapy treatments have improved survival rates for many patients, their effectiveness can stall or fail when tumour cells hide and then spread.How the Smart Drug WorksResearchers in Oxford have developed a drug designed to stop cancer cells concealing themselves from the immune system, allowing immunotherapy treatments to identify and destroy them. In a trial spanning the UK, France, Spain and Australia, 83 patients with cervical, bladder, liver, bowel, lung or head and neck cancers were given the experimental drug, GRWD5769, alongside the immunotherapy treatment cemiplimab.The smart drug was able to remove "invisibility cloaks" from tumour cells, exposing them to the parts of the immune system that attack infections and diseases. This allowed the cemiplimab immunotherapy to pinpoint and destroy the cancer.Trial Results Across Cancer TypesResearchers, led by the Christie NHS foundation trust in Manchester, England, found that tumours shrank in 26 patients. Of those, 15 experienced tumour reductions of at least 30%. All participants had previously failed to respond to treatment, and most had no options left when they joined the study.GRWD5769 was shown to shrink tumours in all six cancer types included in the trial. The drug halted progression of the disease for at least six months in 18% of cervical cancer patients, 32% of liver cancer patients, 36% of bladder cancer patients, 38% of those with neck and head cancer, and more than half of bowel (51%) and lung (55%) cancer patients.Significance for Cancer TreatmentImmunotherapy enlists T-cells – immune system cells that attack infections and diseases – to hunt and destroy cancer. Although it has revolutionised cancer care, it fails in about two-thirds of patients. This is because immunotherapy struggles when tumours hide from the immune system.Tumours can evade the immune system by manipulating an enzyme called ERAP1 (endoplasmic reticulum aminopeptidase 1). By altering this enzyme, cancer cells can hide from a patient's T-cells. GRWD5769 solves this problem by inhibiting ERAP1, which removes cancer's invisibility cloak and makes tumour cells visible to T-cells that could not previously find them.Future Outlook for Cancer TreatmentThe findings were presented at the American Society of Clinical Oncology's annual meeting in Chicago, the world's largest cancer conference. Prof Fiona Thistlethwaite, the principal investigator, noted: "For a drug that is given as a tablet, this is very impressive. It's early days, and we need further studies, but this is a new drug with a new mechanism that clearly helps immunotherapy perform more effectively."The tablets, which were developed by Oxford-based Greywolf Therapeutics and were tolerated well by patients. The trial remains ongoing, with a larger study planned. Cancer Research UK's research information lead, Dr Samuel Godfrey, noted: "Immunotherapy has transformed treatment for some cancers but it doesn't yet work for everyone. This trial seems to show how this new drug could make immunotherapy more effective, including in some cases where immunotherapy had previously failed."